Publications by authors named "K C Keith"
Background Context: Ropivacaine-Epinephrine-Clonidine-Ketorolac (RECK) cocktail can improve pain control in patients undergoing lumbar decompression. Given the aging population, rising healthcare costs, the opioid epidemic, and associations of acute pain control with long-term opioid use, effective opioid-sparing analgesia following spinal fusion surgery may impart societal benefits.
Purpose: We aimed to investigate whether RECK was an effective local anesthetic for patients undergoing posterior spinal fusion.
Background: The purpose of this study was to compare patient-reported outcomes measures, complication rates, and return to hospital in a cohort of patients undergoing anatomic total shoulder arthroplasty (aTSA) or reverse total shoulder arthroplasty (rTSA) with at least one functional somatic syndrome (FSS) to a control cohort.
Methods: A retrospective review identifying patients who underwent rTSA or aTSA from 2015 to 2022 was performed. Patients with one or more FSS diagnosis (irritable bowel syndrome, chronic headache, chronic low back pain, or fibromyalgia) were compared against a control cohort.
Article Synopsis
- The Open Pediatric Cancer (OpenPedCan) Project builds upon the earlier Open Pediatric Brain Tumor Atlas, analyzing data from over 6,000 pediatric cancer patients and providing a vast multi-omic dataset from various tumor types.
- The project integrates multiple genomic and proteomic data types, allowing researchers to access harmonized data through platforms like GitHub, CAVATICA, and AWS.
- OpenPedCan enhances molecular subtyping of tumors by incorporating methylation information, facilitating research that supports more accurate diagnosis and treatment strategies in pediatric cancer.
Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection inhibits mitochondrial oxidative phosphorylation (OXPHOS) and elevates mitochondrial reactive oxygen species (ROS, mROS) which activates hypoxia-inducible factor-1alpha (HIF-1α), shifting metabolism toward glycolysis to drive viral biogenesis but also causing the release of mitochondrial DNA (mtDNA) and activation of innate immunity. To determine whether mitochondrially targeted antioxidants could mitigate these viral effects, we challenged mice expressing human angiotensin-converting enzyme 2 (ACE2) with SARS-CoV-2 and intervened using transgenic and pharmacological mitochondrially targeted catalytic antioxidants. Transgenic expression of mitochondrially targeted catalase (mCAT) or systemic treatment with EUK8 decreased weight loss, clinical severity, and circulating levels of mtDNA; as well as reduced lung levels of HIF-1α, viral proteins, and inflammatory cytokines.
View Article and Find Full Text PDF